CACNA1D and prostate carcinoma: VGCC subunit CaV1.3 contributes to resistance against androgen deprivation therapy in prostate cancer [176], while the α2δ-1 subunit encoded by CACNA2D1 has been shown to enhance radioresistance in NSCLC [177].